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Heart Failure
“ Science can amuse and fascinate us all, but it is engineering that 
changes the world.”
– Isaac Asimov, 1920–1992
Technological breakthroughs, particularly advances in devices, are 
changing the course of heart failure (HF) management. Implantable 
devices have been used for decades to treat heart disease. The first 
pacemaker was implanted over 60 years ago (October 1958), and 
implantable defibrillators were first used in the early 1980s. Cardiac 
resynchronisation therapy appeared at the turn of the century. 
However, the past few years have witnessed a surge in both the types 
of devices being tested for HF treatment and the optimism of experts 
about their usefulness. 
This HF Special Focus Section reviews novel devices used for advanced, 
symptomatic HF. Destination left ventricular assist devices (LVADs) in 
non-transplant centres, interatrial shunts to treat HF and MitraClip in HF 
are discussed by Bayés-Genis, Rodés-Cabau and Linderfeld. 
The history of mechanical circulatory support began in 1953, when 
John H Gibbon reported the first successful use of extracorporeal 
circulation by means of an oxygenator. In 1966, DeBakey implanted the 
first pneumatically driven LVAD,1 and in 1969, Cooley implanted the first 
total artificial heart, intended as a bridge to transplantation.2 It was not 
until 1982 that the Jarvik-7 artificial heart was implanted for the first 
time with the intention of permanent treatment, although the patient 
died within 4 months of severe sepsis and multi-organ failure.3
A shift from the concept of a complete artificial heart towards the 
development of single chamber pumps as cardiac support initiated the 
LVAD era. First-generation ventricular assist devices were either 
pneumatically or electrically driven membrane pumps, such as the 
Berlin Heart EXCOR (Berlin Heart) and Thoratec PVAD (Thoratec). 
In the past decade, LVAD systems have undergone substantial progress 
in size, durability, reliability and noise emission, such as the HeartMate 3 
(Abbott Structural Heart). LVAD implantation became a new treatment 
option for end-stage HF, as destination therapy for patients either too 
old or not suitable for transplantation due to other medical conditions. 
Consequentially, an exponential increase in LVAD implantations has 
occurred in the past 5 years.
The history of the MitraClip begins with advances in the surgical 
treatment of mitral regurgitation. The MitraClip technology draws on 
experience with surgical edge-to-edge mitral valve repair, which was 
first reported by Alfieri et al. in 1995.4 This technique involves the 
placement of sutures to anchor the free edge of a leaflet to its 
corresponding opposite leaflet, creating two valve orifices without the 
need for annuloplasty.
Based on these findings, investigators at major academic institutions, 
in concert with private industry (Evalve; later Abbott Vascular), 
developed the MitraClip percutaneous transcatheter method to 
reapproximate the anterior and posterior mitral leaflets as a therapy for 
mitral regurgitation. This method was first described in pigs in 2003, 
and several trials have since tested the value of MitraClip in the 
treatment of severe mitral regurgitation, with controversial results. 
In this HF Special Focus Section, these data are discussed and put 
into a clinical context to better understand the real clinical value of 
MitraClip in 2020. 
The interatrial shunt is the newest of the three devices discussed in this 
special issue. Increased left atrial pressure leading to pulmonary 
congestion is the common mechanism precipitating symptom 
worsening and acute decompensation in chronic HF patients. Some 
evidence supports interatrial shunting to relieve the excess volume 
from the left to right atrium regulated by the interatrial pressure 
gradient. 
Two different interatrial shunt devices are currently being tested in 
large randomised clinical trials: the interatrial shunt device (Corvia 
Medical) and the V-Wave device (V-Wave). Both are intended for 
symptomatic HF; the interatrial shunt device is focused on heart failure 
with preserved ejection fraction, whereas the V-Wave device is being 
tested in both heart failure with preserved ejection fraction and heart 
failure with reduced ejection fraction.5 
We have truly entered the era of devices in HF, and I believe there will 
be rapid progress on multiple fronts in the next few years. These 
devices would have been completely unimaginable a few decades ago, 
and exemplify the role that industry and technology play in modern 
medical care. 
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Furthermore, while advances in devices are impressive, it is likely that 
we are only in the early stages of their development. These new 
devices may just be the second wave designed for different aspects 
of HF treatment, after implantable defibrillators and cardiac 
resynchronisation therapy. What we do now may be called a ‘passive’ 
bridge to recovery, where we place devices and hope that whatever is 
wrong with the heart naturally works itself out. What we may see in 
the future is an ‘active’ bridge to recovery, where we not only place 
the device, but administer cells, genes or new (or even old) drugs to 
help repair the heart. 
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